Tech

High Growth Tech Stocks To Watch In Asia April 2026

As global markets navigate a complex landscape marked by geopolitical tensions and economic shifts, the Asian tech sector continues to capture attention with its potential for high growth, especially as AI-related investments gain momentum. In this environment, identifying promising tech stocks involves assessing companies’ ability to innovate and adapt to changing consumer demands while effectively managing costs amidst rising inflationary pressures.

Name

Revenue Growth

Earnings Growth

Growth Rating

Zhongji Innolight

41.90%

44.62%

★★★★★★

Giant Network Group

29.03%

42.89%

★★★★★★

Shengyi Electronics

26.58%

33.04%

★★★★★★

Suzhou TFC Optical Communication

41.81%

38.74%

★★★★★★

Unimicron Technology

23.36%

51.25%

★★★★★★

Fositek

29.09%

38.55%

★★★★★★

Digital Arts

21.36%

26.45%

★★★★★★

PharmaEssentia

32.44%

50.27%

★★★★★★

Co-Tech Development

34.37%

65.79%

★★★★★★

CARsgen Therapeutics Holdings

64.21%

83.56%

★★★★★★

Click here to see the full list of 122 stocks from our Asian High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market capitalization of ₩19.75 trillion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to approximately ₩215.86 million. The focus on developing innovative biotechnological solutions positions it in a niche market within the biotech industry.

Alteogen has recently demonstrated a robust trajectory in the biotech sector, particularly with its strategic alliance with Biogen Inc., which not only brought an immediate $20 million upfront but also opens potential for up to $549 million in milestone payments. This partnership leverages Alteogen’s proprietary Hybrozyme technology, underscoring its innovative edge in subcutaneous drug formulations. Financially, Alteogen’s revenue and earnings have surged impressively, with annual revenue growth at 45.2% and earnings growth accelerating by 127.6% over the past year, significantly outpacing the industry average of 32.2%. This performance is bolstered by a forecasted annual profit growth of 58%, highlighting Alteogen’s strong market position and promising outlook in high-growth biotechnological advancements.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button